Esketamine in a Patient With Major Depressive Disorder and Polysubstance Use: A Case Report.
Cureus October 1, 2025 Abdelazim Ali, Nahida Ahmed, Sona Varghese
Major depressive disorder (MDD) frequently co-occurs with substance use disorders (SUDs), leading to poorer outcomes and limited options. Esketamine is approved for treatment-resistant depression (TRD); its effects on craving and abstinence in SUD are less explored. A 41-year-old man with recurrent MDD (suicidal ideation) and polysubstance use (daily morphine/prescription opioids; intermittent...